Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SRN-101 Prior to Surgical Resection in Recurrent High-Grade Glioma
NCT07826949Phase 1Not yet recruiting
- Sponsor
- Nicholas Butowski
- Start
- Nov 2026
- Primary completion
- Apr 2027
- Countries
- 1
01
Overview
Phase 1, open-label trial of AAV-hIFNβ in glioma (2 arms), sponsored by Nicholas Butowski. Primary endpoints: Proportion of participants reporting treatment-emergent adverse events at 21 days, Proportion of participants reporting adverse events of special interest at 21 days and 2 more. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
AAV-hIFNβ
03
Conditions
glioma
Beyond the preview
Go deeper on NCT07826949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07826949.